What this pack is
Methycobal is the brand name in this record; mecobalamin (methylcobalamin) is the generic name. Read both together with the dosage form (exact dosage form to be checked from the current pack).
PACK CHECK · MARKET FIRST
MethycobalGeneric namemecobalamin (methylcobalamin)
Mainland China pack-name cue弥可保®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
Mecobalamin is a form of vitamin B12 used for peripheral neuropathies. It helps chemical processes needed by nerve cells; it is not a promise of immediate pain relief.
Read source: Japan ↗reviewed 2026-09-09More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 弥可保®
- International brand name
- Methycobal
- Source-scoped market brand names
- メチコバール / Methycobal · JapanSource-scoped evidence ↗The Japanese original separates 250/500 microgram tablets from fine granules.
- METHYCOBAL · SingaporeSource-scoped evidence ↗The government record identifies a 500 MCG sugar-coated tablet, SIN06291P, held by EISAI (SINGAPORE).
- 弥可保® · Mainland ChinaHistorical public record ↗A brand clue from a 2018 company announcement, not a current Chinese leaflet.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- mecobalamin (methylcobalamin)
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
Mainland China trade-name search cue:弥可保®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
2 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
JP · PMDA electronic label, April 2023, first revision
250 micrograms mecobalamin per tablet; 100-tablet pack
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- 15400AMZ01326000
- Form and route
- Mecobalamin sugar-coated tablets · Oral (product identity)
- Listing review
- Cited product evidence reviewed 2026-09-09; actual marketing, stock and availability are not established.
- mecobalamin
- 250 μgStrength per tablet, not an individual dose
- Package
- 100 tablets per pack
JP · PMDA electronic label, April 2023, first revision
500 micrograms mecobalamin per tablet; 100-tablet pack
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- 15400AMZ01327000
- Form and route
- Mecobalamin sugar-coated tablets · Oral (product identity)
- Listing review
- Cited product evidence reviewed 2026-09-09; actual marketing, stock and availability are not established.
- mecobalamin
- 500 μgStrength per tablet, not an individual dose
- Package
- 100 tablets per pack
PACKAGE-VISUAL STATUS
Japanese tablet images are in the original; no substitute carton photo
Use the Japanese patient guide to inspect tablet appearance. No exact carton photograph has been verified here. Retail, injection or other-market images are not substituted; appearance alone cannot authenticate medicine.
LABEL READING · NOT A PRESCRIPTION
Large-print leaflet reading: units before tablet counts
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The Japanese label is dated April 2023 and its patient guide May 2026. They serve different purposes. Check the Chinese original for a Chinese pack; access dates are not revision dates.
- μg (also mcg) means micrograms; mg means milligrams. 500 μg = 0.5 mg and 250 μg = 0.25 mg. Unit conversion explains strength, not your tablet count.
- Have the prescribed amount, frequency and actual strength checked together. “Half a milligram” is not an instruction to halve a tablet or substitute injections or granules.
- The Japanese label cautions against continuing for over a month without benefit. Arrange reassessment rather than increasing the dose or assuming all numbness is vitamin deficiency.
- The Japanese patient guide lists appetite loss, nausea, vomiting and diarrhoea among possible effects. Contact a clinician or pharmacist about new or unusual symptoms.
- Remove the tablet from its blister before swallowing; never swallow a cut-out blister cell. The Japanese guide advises protection from light and moisture; check your actual pack’s storage directions.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkPMDA · Japan · Regulatory product record · 2026-09-09
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- Japan · 1
- Singapore · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routePMDA: Methycobal tablets 250 / 500 micrograms and fine granules; April 2023 label ↗reviewed 2026-09-09
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- Singapore National Drug Formulary (NDF) · Singapore · Government drug formulary product information and leaflet excerpts · 2026-09-09Singapore National Drug Formulary: METHYCOBAL TABLET 500 MCG, SIN06291P; updated 28 July 2026 ↗reviewed 2026-09-09
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Methycobal (mecobalamin (methylcobalamin)). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Methycobal is the brand in this record and mecobalamin (methylcobalamin) is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- PMDA: Methycobal tablets 250 / 500 micrograms and fine granules; April 2023 label ↗reviewed 2026-09-09
- PMDA: Methycobal patient guide, May 2026 ↗reviewed 2026-09-09
- Singapore National Drug Formulary: METHYCOBAL TABLET 500 MCG, SIN06291P; updated 28 July 2026 ↗reviewed 2026-09-09
HOW IT WORKS · NOT A TREATMENT PLAN
Supports cellular metabolism; more does not mean better nerves
- In more detail, it acts as an enzyme helper in converting homocysteine to methionine. This is not a basis for selecting treatment from a single laboratory result.
- A mechanism does not identify the cause of your numbness or determine treatment duration; suitability depends on diagnosis.
- A B12 label does not make products identical. Review multivitamins, other B12 preparations and all medicine packs together to avoid omissions or duplication.
- The patient guide asks users to disclose this medicine at other clinics or when buying other medicines. This site does not infer combination safety from the word vitamin.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- PMDA: Methycobal tablets 250 / 500 micrograms and fine granules; April 2023 label ↗reviewed 2026-09-09
- PMDA: Methycobal patient guide, May 2026 ↗reviewed 2026-09-09
- Singapore National Drug Formulary: METHYCOBAL TABLET 500 MCG, SIN06291P; updated 28 July 2026 ↗reviewed 2026-09-09
- Eisai China: Suzhou oral solid-dose factory announcement, 11 January 2018; historical Methycobal brand evidence ↗Historical public record · reviewed 2026-09-09
SOURCE-TRACEABLE ARCHIVE
Methycobalmecobalamin (methylcobalamin)
This page links to public primary-source material for Methycobal. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Japanese 500 microgram tablet sales began
A product-specific Japanese sales date, not a global-first claim.
PMDA: Methycobal tablets 250 / 500 micrograms and fine granules; April 2023 label ↗Oral solid-dose manufacturing history in China
Eisai’s announcement described Suzhou factory plans and separated oral products from injection manufacturing. Historical plans are not presented as today’s output.
Eisai China: Suzhou oral solid-dose factory announcement, 11 January 2018; historical Methycobal brand evidence ↗
MARKET SCOPE
Market-record boundary
Mainland China
Historical brand clue; current leaflet not verifiedA current Chinese official leaflet and independent NMPA record have not been verified. Approval IDs, packs, prices and inventory are not invented.
Japan
Public PMDA originals checkedThe two 100-tablet presentations are Japanese identity examples, not all pack sizes or live supply.
Singapore
Government product record checkedSIN06291P identifies a 500 MCG sugar-coated tablet. Its local classification does not transfer to other countries or mean this site sells it.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Is 500 μg more than 0.5 mg?
No: these express the same amount. 500 mg is a thousand times 0.5 mg; read the number and unit together when checking with your pharmacist.
Can I freely add a vitamin medicine?
Do not add or increase treatment merely because it is a vitamin. Review all medicine and supplement ingredients, symptoms and duration of use.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.